Thank you Sukh @SukhNijjer for tweeting this interesting slide. 
@SukhNijjer This is saying that you are taking an up-front risk of periproc MI's, which are repaid over time with less spontaneous MIs.
If you count all MIs as equal, apparently at 5 years the total is not significantly different between arms. (Looks like numerically a tiny bit less with invasive)
If, on the other hand, you count spontaneous MIs as WORSE than periproc MIs, then you might feel that the point of crossover of net "weighted" MIs is a bit earlier.
Moreover the longer one were to look over time, the more likely the MIs (weighted or not) would be to be significantly less in the invasive arm.
I am going to tell my cath lab colleagues this good news to soften the blow.
We (already know we) aren't saving lives.
We accept that there is a bit of perioproc MI, but now see a gradual annual saving of spontaneous MIs. After (about 4?) years there is a net reduction of MIs.
We (already know we) aren't saving lives.
We accept that there is a bit of perioproc MI, but now see a gradual annual saving of spontaneous MIs. After (about 4?) years there is a net reduction of MIs.
This is going to be my official good news to cheer staff up, especially the unlucky ones working over Xmas-New-year.
Father Stentmas's message of good cheer.
Father Stentmas's message of good cheer.
I won't bother with the symptom relief stuff.
These are the staff who carried out the excellent blinding of the ORBITA trial, whom @rallamee has vigorously coached on the necessity of blinding for symptom evaluation, so they would just laugh at me.
These are the staff who carried out the excellent blinding of the ORBITA trial, whom @rallamee has vigorously coached on the necessity of blinding for symptom evaluation, so they would just laugh at me.
@rallamee Aaargh. Before I get beaten up: this is a non-significant trend, which I am elevating a little on the grounds of biological plausibility, and the fact that trials have to end someday, but benefits can continue to accrue.
